Clinical trial
A Randomized, Open-label Study of Lobaplatin/Etoposide as First Line Therapy With or Without Anlotinib Maintenance Therapy in Patients With Extensive-stage Small-cell Lung Cancer
NCT03700359 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Guangzhou Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-label Study of Lobaplatin/Etoposide as First Line Therapy With or Without Anlotinib Maintenance Therapy in Patients With Extensive-stage Small-cell Lung Cancer
- Lead sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- March 1, 2019
- Completion date
- November 29, 2021
- Enrollment
- 60 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.